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Guided Bone Regeneration Using
Injectable Vascular Endothelial Growth
Factor Delivery Gel
Darnell Kaigler,*† Eduardo A. Silva,‡ and David J. Mooney‡
Background: Vascularization underlies the success of
guided bone regeneration (GBR) procedures. This study
evaluates the regenerative potential of GBR in combination
with vascular endothelial growth factor (VEGF) delivery via
an injectable hydrogel system.
Methods: Critical-sized defects were created in rat calvar-
iae, and GBR procedures were performed with a collagen
membrane alone (control), or plus bolus delivery of VEGF,
or plus application of VEGF-releasing hydrogels (VEGF–Alg).
Four and 8 weeks after treatment, defect sites were evalu-
ated with microcomputed tomographic and histomorpho-
metric analyses for blood vessel and bone formation.
Results: At 4 weeks, relative to the control condition, the
bolus addition of VEGF did not affect blood vessel density
within the defect site, yet the application of VEGF–Alg signi-
ficantly (P <0.05) increased blood vessel density. Although
there was no difference in bone regeneration at 4 weeks, at
8 weeks there was a significant (P <0.05) increase in bone
regeneration in the VEGF–Alg-treated defects.
Conclusions: These data demonstrate that the application
of VEGF–Alg enhanced early angiogenesis, whereas at
a later time point, it enhanced bone regeneration. Controlled
delivery approaches of angiogenic growth factors used
adjunctively with GBR may be a promising strategy for en-
hancing outcomes of GBR. J Periodontol 2013;84:230-238.
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M
anagement of bone deficiencies
may comprise a significant part
of treatment for individuals
undergoing dental prosthetic rehabi-
litation, particularly those being restored
with dental implant therapy. Current
strategies used to treat these defici-
encies often involve various alveolar
bone grafting procedures.1-4 In most
instances, these approaches use auto-
genous, allogenic, or alloplastic bone
grafts for bone regeneration.5,6 Regard-
less of the material used, it is well docu-
mented that the development of a
supporting vasculature concomitant to
graft maturation is a key determinant to
optimize bone regeneration at grafted
sites.7,8
Since it was first introduced, guided
bone regeneration (GBR) has become
a routine treatment modality for the
regeneration of alveolar bone.9 The fun-
damental concept underlying GBR is
to exclude specific cell types from the
regenerative site while enabling the
incorporation of others.10 Barrier mem-
branes are used to provide this cell-
exclusive feature, and commonly, a bone
graft material is also used for space
maintenance. Nonetheless, regardless of
the clinical protocol and materials used
in GBR, it is understood that central to
its success is the angiogenic response,
establishing the vasculature to ultimately
support the regenerated tissue.11,12
Thus, angiogenesis is ultimately a criti-
cal determinant of bone regeneration.
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To this end, there are several studies that have
aimed to address this issue by adjunctively using
a commercially available growth factor, platelet-
derived growth factor (PDGF), in combination with
bone grafting procedures for enhancement of bone
regeneration.13-17 Although PDGF acts primarily
through its chemotactic and proliferative proper-
ties, it has demonstrated the ability to enhance
angiogenesis as well. Although regenerative success
has been shown with this approach, there have been
no controlled studies to determine whether bolus
delivery of a growth factor in this manner makes
a difference.18,19 Coupled with the relatively short
half-life of growth factors and that during and after
surgery much of the growth factor undoubtedly is
diluted out by the patient’s own blood, a relatively
small fraction of the initial volume is what probably
actually remains in the defect site.
As such, an approach to address this limitation
could be to deliver an angiogenic growth factor in
a controlled, sustained manner to the regenerative
site. We have demonstrated previously the ability
to develop hydrogels that incorporate growth factors
that can be predictably released during a sustained
period of time in a localized manner.20,21 As men-
tioned, PDGF has been used clinically for treatment
of osseous defects, but it has not been used specifi-
cally to promote angiogenesis. Vascular endothelial
growth factor (VEGF) is a more potent angiogenic
growth factor and thus may serve as a good candi-
date for delivery as part of GBR procedures.22-24 In
the context of therapeutic angiogenesis, we have
demonstrated that localized, sustained delivery of
VEGF using hydrogels is efficacious in a number of
different model systems.25-29 This study addresses
the hypothesis that GBR, combined with controlled
sustained delivery of VEGF, can enhance the angio-
genic response and, hence, bone regeneration in
a critical-sized osseous defect (a defect in which
complete regeneration will not occur unless an in-
tervention is performed).30 The rationale underlying
this approach is to turn a passive cell-exclusion pro-
cedure into a more active regenerative process.
MATERIALS AND METHODS
VEGF-Releasing Alginate Hydrogel Fabrication
An alginate delivery system was formulated using
a bimolecular molecular weight (MW) alginate com-
posed of two polymer components, low and high
MW alginate polymer solutions, as described pre-
viously.29 Briefly, ultrapure alginates§ were used as
the high MW (250 kDa) component. Low MW algi-
nate (50 kDa) was obtained by gamma-irradiating
highMWalginate at a gamma dose of 3.0mrad.iThe
injectable delivery alginate system was formulated
by combining the two different MW polymers at a ratio
of 7.5:2.5. Both alginate polymers were diluted to
1% weight/volume in ddH2O, and 1% of the sugar
residues in the polymer chains were oxidized with
sodium periodate.¶ To gel the alginates’ solutions,
the sterile oxidized alginate stock was reconstituted
to a 2% weight/volume solution in basal Eagle’s
basal medium (EBM) phenol red–free# overnight and
subsequently was mixed with recombinant hu-
man VEGF165 (0.06 mg/mL alginate gel)** and
a 0.21 g/mL calcium sulfate slurry (25:1 alginate/
calcium solution) via a syringe connector. The mix-
ture was allowed to gel in the syringes for 30 minutes
and then was maintained at 4C before animal ap-
plications. For the in vitro mechanical analysis, the
gels were stored at 37C in EBM for 24 hours
before testing.
Characterization of Hydrogels
The capability of alginate hydrogels to be used as
an injectable delivery system was evaluated by
characterizing the rheologic properties of pregelled
solutions, as previously described.29 Briefly, the vis-
cosities of alginate solutions (pregelled) were moni-
tored by using a controlled-stress rheometer†† at
a constant temperature of 25C. Before the quanti-
fication, all samples were presheared at a high shear
rate, followed by rest for 5 minutes. While increasing
the shear stress from 0.008 to 10 Pa, the resulting
strains were measured, and the corresponding vis-
cosity (h) was calculated (0.0553 Pa/second). Osci-
llatory shear experiments were conducted on the
alginate samples using a cone-plate system. The
rheometer was operated in the frequency sweep
mode from 0.20 to 62.75 rad/second-1 at a strain of
0.005. During testing, storage modulus (G9) was re-
corded as a function of frequency.
The degradation of hydrogels formed from a com-
bination of high and low MW polymers that were
partially oxidized (1%) was evaluated by dry weight
loss as a function of degradation time. The degra-
dation behavior was further examined by quantifying
changes in the elasticmoduli (E) through time in vitro.
The E of the gels was measured by compressing at a
constant deformation rate of 1 mm/second with
amechanical tester‡‡ at25C,asdescribed indetail by
Kong et al.31
Critical-Sized Calvarial Defect Model and GBR
Treatment of experimental animals was in ac-
cordance with the University of Michigan animal
care guidelines, and all National Institutes of Health
§ Pronova UP MGV, NovaMatrix, Sandvika, Norway.
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animal handling procedures were observed. Critical-
sized defects in 30 Fischer rats (175 to 200 g)§§ were
created, with one defect being created in each rat,
as described previously.32 Briefly, a midlongitudinal
incision was made on the dorsal surface of the head
and skin, and the periosteumwas reflected to expose
the calvaria. A trephine bur was next used to create
an 8-mm circular defect in the cranium, and care
was taken to remove the full thickness (1.5 to 2 mm)
of the calvarial bone. After creation of the defect,
resorbable collagen membranesii were immediately
placed over the defects alone as a GBR procedure
(control), in combination with a 50 ng/mL VEGF
saline solution added on top of the membrane
(VEGF), or with topical application of the VEGF
hydrogel on top of the membrane (VEGF–Alg).
Microcomputed Tomographic Analyses
Four and 8 weeks after GBR, regenerated tissue
within the defect site was evaluated with micro-
computed tomographic (mCT) and histomorpho-
metric analyses. Three-dimensional reconstructions
of µCT images of the non-decalcified calvariae were
used to determine bone mineral density (BMD) and
bone volume fraction (BVF) as described pre-
viously.32 Briefly, software¶¶ was used to generate
three-dimensional reconstructions of the calvaria
using images scanned in two-dimensional µCT.##
For analysis of mineralized bone, a threshold value
of 1,100 was used. Using three-dimensional images
of the specimens, the total volume (TV; cubic milli-
meters), bone volume (BV; cubic millimeters), and
BMD of tissue within the defect site were measured
directly, and the fractional bone volume (BV/TV;
percentage) was calculated from the BV and TV
measures.
Blood Vessel Formation/Bone Histomorphometry
Four and 8 weeks after GBR, the regenerated tissue
was harvested, and neovascularization was assessed
through histologic analysis. Samples from hematox-
ylin and eosin-stained tissues in each condition were
analyzed for blood vessel and bone formation man-
ually and digitally as described previously.33 Briefly,
total blood vessels were counted in each histologic
section based on the presence of endothelial cells
lining well-defined capillary lumens containing red
blood cells. The vessel number was then divided by
the total area of the section to report the blood vessel
density as vessels per squared millimeter. For bone
histomorphometry, identification of bone was based
on morphology of eosin-stained tissue and the cells
lining(osteoblasts)andwithin (osteocytes) this tissue.
This area was divided by the total area of the section
and was reported as the percentage of the bone area/
tissue area (BA/TA; percentage).
Statistical Analyses
The statistical analyses were performed using soft-
ware.*** For between-group comparisons, the me-
dian and interquartile ranges (IQRs) for the blood
vessel counts and bone measures were reported,
unless otherwise noted. For within-group compari-
sons (with time), differences in the sample means
were reported with standard errors of the means.
Descriptive analyses were performed initially, and
for between-group comparisons, a non-parametric
(Kruskal-Wallis) test was used to test for statistical
significance between groups, which was defined as
P <0.05. For within-group comparisons between




The degradation rate of the alginate hydrogels
formed from partially oxidized alginate was rapid,
with significant mass loss within 7 days (50%) and
almost complete mass loss by 40 days (Fig. 1A).
Changes in the E with time were quantified in vitro
and showed that the binary gels displayed a gradual
reduction in E during the first 2 weeks, supporting
their degradation in physiologic medium (Fig. 1B).
During examination of the rheologic properties of
pregelled solutions formed from a combination of
low and high MW alginates (binary gels), they ex-
hibited an intermediate G9 compared to gels formed
from the high or low MW polymers alone (Fig. 1C).
All three gel types demonstrated a modest de-
pendence of G9 on the shear frequency, as expected
for viscoelastic gels. The in vivo localization of
VEGF released from these hydrogels has been
established previously.29,34,35
Effects of VEGF on Neovascularization in GBR
Sites
At 4 weeks, defect sites from all three conditions
exhibited an abundant vascular response indicative
of granulation tissue formation within a wound
healing site. Although numerous capillaries were
present in all conditions, blood vessel densities in
the sites treated with VEGF–Alg (Fig. 2A) quali-
tatively appeared higher than densities in regen-
erated tissues of the sites treated with bolus delivery
of VEGF (VEGF) or only GBR (control). Quantifica-
tion of vessel densities at this earlier time point re-
vealed that blood vessel densities were highest in the
VEGF–Alg group (median =37.1 vessels/mm2; IQR =
12.6), and this higher density was statistically
§§ Charles River Laboratories, Wilmington, MA.
ii BioMend, Zimmer Dental, Miami, FL.
¶¶ MicroView, Parallax Innovations, Ilderton, ON.
## µCT MS8X-130, EVS, Toronto, ON.
*** InStat, GraphPad Software, San Diego, CA.
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significant (P = 0.043) relative to the control group
(25.1 vessels/mm2; 7.9) (Fig. 2B). There was no
statistical difference between the control group and
the VEGF group (33.1 vessels/mm2; 9.7) or between
the two groups treated with VEGF.
During examination of the treated sites at the
8-week time point, the statistically significant in-
crease in neovascularization seen at the early time
point was no longer evident among the groups, al-
though the VEGF–Alg group had more vessels than
the other two groups at this time point (Fig. 2C).
Additionally, when looking at within-group changes
in blood vessel density through time, there were no
significant differences in blood vessel densities from
4 to 8 weeks within any of the three groups (Fig. 2D).
mCT Analyses of Bone Regeneration
Figure 3A shows representative three-dimensional
µCT images from each of the three treatment groups
at 4 and 8 weeks. In all three groups, there was early
(4 weeks) evidence of mineralized tissue formation
within the defect, yet qualitatively, there appeared
to be no difference in mineralized tissue formation
among groups. At 8 weeks, µCT images showed
that more regenerated mineralized tissue was
present within the VEGF–Alg-treated defects than
in the other two groups (Fig. 3B). It was also ob-
served that the best regenerative response at 8
weeks (as measured by highest BMD, BVF, and BA/
TA) among all three conditions (n = 15) occurred in
the VEGF–Alg-treated group, as shown in Figure 3B.
Quantitative µCT analyses confirmed the qualita-
tive evaluation and revealed that, although early
bone formation was achieved in each of the three
groups, among the three groups, there were no dif-
ferences in regenerated mineralized tissue as mea-
sured by BMD and BVF. Although there were no
differences in these parameters among groups at
the early time point, with time in the VEGF–Alg
group, there were significant increases (P <0.01) in
BMD (mean difference = 184 mg/cc) and BVF (mean
difference = 0.27). Additionally, at 8 weeks, quanti-
tative µCT analyses of BMD showed that the VEGF–
Alg group had significantly higher BMD (median =
–234.5 mg/cc; IQR = 48.4) than the VEGF group
Figure 1.
Characterization of hydrogels. A) In vitro degradation of binary alginate
gels as monitored by mass loss through time. The dry masses of gels
formed from binary MW partially oxidized alginate were analyzed as
a function of time after incubation in phosphate-buffered saline (pH 7.4)
at 37C. Values represent mean and standard deviation (n = 5). B) E of
binary hydrogels as a function of time in vitro (1% oxidized). E0 represents
the initial E of the gels measured after incubation for 24 hours, and all
values were normalized to this initial modulus. Values represent mean
and standard deviation (n = 4). C) G9 of binary hydrogels (Binary), gels
comprised of only high MWalginate (High MW), and gels comprised of
only low MW polymer (Low MW), as a function of the strain frequency.
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(164.7 mg/cc; 37.2; P = 0.041)
and the control group (138.8
mg/cc;76.2;P=0.036)(Fig.3C).
Similarly, BVF in the VEGF–
Alg group (median = 0.33; IQR =
0.07) was significantly higher
than in the VEGF (0.25 mm/cc;
0.09; P = 0.031) and control
(0.16 mg/cc; 0.12; P = 0.023)
groups at 8 weeks (Fig. 3D).
Histologic Analyses of Bone
Regeneration
Histologic evaluation of speci-
mens at this time point con-
firmed that the mineralized
tissue seen in the µCT ana-
lyses had morphology con-
sistent with that of bone tissue
(Fig. 4A), and at this later time
point, there were also speci-
mens among the three groups
that exhibited complete bridg-
ing of the critical-sized defect
with regenerated bone tissue
(Fig. 4B). Three of the five
specimens in the VEGF–Alg
group had complete regenera-
tion across the defect, whereas
only one specimen in each of
the other two groups exhibited
complete bridging. Quantitative
histomorphometric analysis of
bone area was consistent with
the µCT analysis in that, at 4
weeks, there was no difference
in bone area (BA/TA) among
the three groups, but with time
in the VEGF–Alg group, BA/TA
significantly increased (mean
difference = 25%) (Fig. 4C).
Finally, at the 8-week time
point, the VEGF–Alg-treated
group (median = 35.5%; IQR =
19.2) had the highest BA/TA
relative to the VEGF (18.5;
13.1; P = 0.039) and control
(23.9; 22.7; P = 0.047) treat-
ment groups (Fig. 4C).
DISCUSSION
Central to the success of GBR
procedures is the ability of the
barrier membrane to control
(‘‘guide’’) thecells thatpopulate
the regenerative site through
Figure 2.
Angiogenesis within defect sites. A) Photomicrographs of representative histologic (hematoxylin and
eosin-stained) sections taken from control, VEGF-treated, and VEGF–Alg-treated defect sites at 4
and 8 weeks. Vessels are characterized by the presence of red blood cells within defined lumens lined by
endothelial cells. B) Box plots represent the median (x), IQR (limits of box), minimum (lower limit of
bottom line), and maximum (upper limit of top line) numbers of blood vessels among control, VEGF, and
VEGF–Alg conditions at 4 weeks (n = 5). C) Box plots representing blood vessel densities at 8 weeks.
D) Graphs represent the mean – SEM of blood vessel densities at 4 and 8 weeks among and within
conditions. *P <0.05 relative to control condition
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cell exclusion of undesirable (epithelial) cells and
inclusion of desired (osteogenic and vascular) cells.
In this regard, the membrane functions in a passive
manner, yet the key factor underlying success of
the regenerative response is vascularization of the
site.11 In this report, we aim to make GBR more
‘‘active’’ through using a controlled growth-factor
delivery system to enhance the vascular response to
the regenerating site. Combining oxidized low and
high MW alginates enabled control of the degrada-
tion rate to maintain favorable viscous and me-
chanical properties for use in this GBR indication.
Figure 3.
mCT analyses of bone regeneration. Representative three-dimensional reconstructed mCT images across calvarial defects from control, VEGF, and VEGF–
Alg conditions at 4 (A) and 8 (B) weeks (also shown is best regeneration of defect among all conditions, as measured by BMD and BVF). mCT analyses
of BMD (C) and BVF (D) at 4 and 8 weeks. *P <0.05 relative to the same condition at 4-week time point; †P <0.05 relative to control and VEGF
conditions at the 8-week time point.
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GBR procedures were performed in critical-sized
osseous defects, and the barrier membranes used
were coated with VEGF-releasing hydrogels. The
results demonstrated that, relative to the comparison
groups, the VEGF–Alg group increased blood vessel
density early in the regenerative process (4 weeks) and
ultimately enhanced bone regeneration by 8 weeks.
It has been shown recently that delivery of VEGF-
releasing polylactide coglycolide (PLGA) micro-
spheres into critical-sized defects enhances bone
regeneration when used in combination with a PLGA
membrane.36 However, in this report, there is
no evaluation of blood vessel formation, and the
primary outcome measure of bone regeneration
was performed with soft x-ray imaging. We have
also previously evaluated the regenerative potential
of VEGF-releasing scaffolds in non-critical-sized
irradiated bone defects, showing that it enhances bone
regenerationandangiogenesis.32 In thepresent study,
we specifically evaluate the angiogenic response
at an early time point (4 weeks) to determine
whether the hydrogel releasing system affected the
vasculature in the defect site. Although there were no
differences in bone formation at this early time point,
blood vessel formation was significantly enhanced
relative to the control GBR condition.
At the later 8-week time point, we found that there
were no differences in blood vessel densities among
groups or within groups (with time). It is not surprising
that early differences in blood vessel densities among
groups ‘‘wash out’’ with time because the early events
of wound healing rely most heavily on the angiogenic
response.Nonetheless,at the later timepoint,wecould
see significant histologic and radiographic (µCT)
differences in bone regeneration among the VEGF–
Alggroupand theother two groups. Also, interesting
to note was that the VEGF–Alg condition was the only
one in which bone formation significantly increased
with time. The combinatorial effect of sustained VEGF
delivery with GBR would appear to be the cause for
this enhanced regenerative response. It also sup-
ports previous work that suggests that delivery of
VEGF in combination with other materials affects
bone healing and maturation, through indirect pro-
cesses that enhance angiogenesis.37,38 In fact,
when only VEGF is delivered to critical-sized defects,
there is an increase in angiogenesis but no effect
on overall bone regeneration relative to control
conditions.38 However, if another variable (e.g., os-
teoinductive factor, additional material) is incor-
porated in these systems, it appears as though it
can have additive effects to enhance the overall
bone regeneration.37 One of the limitations of our
study is that we do not include a GBR plus alginate
alone group (without VEGF); thus, one could argue
that, although unlikely, the mere presence of algi-
nate itself could be responsible for the results seen.
However, there is no sound basis for this conclusion
because in our previous studies, we have evaluated
the angiogenic effects of alginate, and, regardless of
the regenerative model system evaluated (i.e., bone,
muscle), have never found significant upregulation of
angiogenesis in conditions with only alginate.20,35,39,40
There have been a number of different studies
examining the delivery of different growth factors
to defect sites, yet VEGF, because of its highly
potent angiogenic activities, makes clear sense
for GBR applications. Additionally, VEGF has been
Figure 4.
Histologic analysis of bone regeneration. A) Histologic section (·10)
of the interface (at the defect margin) among native bone (N),
regenerated bone (R), and the membrane (M) from the VEGF–Alg
condition. B) Histologic section (·4) demonstrating complete bridging
across the calvarial defect, seen at 8 weeks in three of the five VEGF–Alg
conditions and in one of the five of each of the control and VEGF conditions
at this time point (black arrows represent margins of calvarial defect).
C) Graph representing histomorphometric bone area analyses (n = 5).
*P <0.05 relative to the same condition at 4-week time point; †P <0.05
relative to control and VEGF conditions.
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implicated in having direct chemotactic and mi-
togenic effects on osteoblasts and osteogenic
cells.41,42 Thus, it could have direct and indirect effects
on bone regeneration as part of GBR procedures.
Failures of these procedures are partially attributed to
inadequate blood supply to support the regenerating
site. This challenge is the rationale for incorporating
other angiogenesis-promoting modalities (i.e.,
platelet-rich plasma, recombinant human PDGF) in
the clinical treatment of large oral reconstruc-
tions using GBR. However, because these angiogenic
agents are delivered as a bolus, their ‘‘availability’’
to the local microenvironment is not well controlled
or sustained with time. Thus, GBR using a controlled
delivery system, which could be either easily injected
into defects or incorporated as part of the material (i.e.,
VEGF-coated membrane), could provide great benefit.
CONCLUSIONS
Overall, this study sought to evaluate the regenera-
tive effects of an injectable VEGF-releasing hydrogel
used as a coating on abioabsorbablemembrane as part
of GBR. Extensions of these findings could have clinical
implications in the development of GBR adjuncts and
even GBR membranes that not only function pas-
sively todirectcellmigrationbutalso function toactively
direct the regenerative process through enhancing an-
giogenesis and, ultimately, bone regeneration.
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